Overexpression of ERCC1-XPF has been linked with poorer prognosis and reduced response to chemotherapeutics in various cancers, including ovarian [24,25], testicular [26], non-small cell lung cancer (NSCLC) [27,28,29], and squamous cell carcinoma [30]. This evidence concerns the gene ERCC4 and non-small cell lung carcinoma.